Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ASND NASDAQ:BMRN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeASNDAscendis Pharma A/S$224.11-5.6%$233.52$158.16▼$250.74$14.81B0.41539,908 shs1.27 million shsBMRNBioMarin Pharmaceutical$57.29+8.6%$54.22$49.26▼$66.28$10.19B0.232.23 million shs5.47 million shs10 Stocks Powering The Next AI Boom The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation. Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceASNDAscendis Pharma A/S-5.63%-9.29%+1.74%-4.02%+40.74%BMRNBioMarin Pharmaceutical+8.63%+5.92%+5.68%-7.19%-1.38%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeASNDAscendis Pharma A/S$224.11-5.6%$233.52$158.16▼$250.74$14.81B0.41539,908 shs1.27 million shsBMRNBioMarin Pharmaceutical$57.29+8.6%$54.22$49.26▼$66.28$10.19B0.232.23 million shs5.47 million shs10 Stocks Powering The Next AI Boom The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation. Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceASNDAscendis Pharma A/S-5.63%-9.29%+1.74%-4.02%+40.74%BMRNBioMarin Pharmaceutical+8.63%+5.92%+5.68%-7.19%-1.38%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceASNDAscendis Pharma A/S 3.00Buy$295.3931.81% UpsideBMRNBioMarin Pharmaceutical 2.75Moderate Buy$88.6754.77% UpsideCurrent Analyst Ratings BreakdownLatest ASND and BMRN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/22/2026BMRNBioMarin Pharmaceutical Canaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$116.00 ➝ $111.005/19/2026BMRNBioMarin Pharmaceutical Bank of AmericaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$85.00 ➝ $80.005/19/2026BMRNBioMarin Pharmaceutical CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$75.005/18/2026ASNDAscendis Pharma A/S CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$355.005/18/2026ASNDAscendis Pharma A/S CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeBuy ➝ Strong-Buy5/18/2026BMRNBioMarin Pharmaceutical CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy5/18/2026BMRNBioMarin Pharmaceutical HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetNeutral$55.00 ➝ $50.005/15/2026BMRNBioMarin Pharmaceutical Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold (C-) ➝ Sell (D+)5/15/2026ASNDAscendis Pharma A/S EvercoreSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform$329.005/11/2026ASNDAscendis Pharma A/S BarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$342.00 ➝ $345.005/11/2026BMRNBioMarin Pharmaceutical The Goldman Sachs GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy ➝ Neutral$69.00(Data available from 5/30/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookASNDAscendis Pharma A/S$814.57M17.16N/AN/A$9.16 per share24.47BMRNBioMarin Pharmaceutical$3.24B3.42$3.10 per share18.48$32.14 per share1.78Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateASNDAscendis Pharma A/S-$258M$8.6725.8521.63N/A57.87%N/A-8.37%8/6/2026 (Estimated)BMRNBioMarin Pharmaceutical$348.90M$1.3741.8210.250.408.29%6.50%5.07%8/3/2026 (Estimated)Latest ASND and BMRN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/7/2026Q1 2026ASNDAscendis Pharma A/S$0.21$0.32+$0.11$11.29$362.47 million$285.45 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthASNDAscendis Pharma A/SN/AN/AN/AN/AN/ABMRNBioMarin PharmaceuticalN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioASNDAscendis Pharma A/S0.791.000.72BMRNBioMarin Pharmaceutical0.235.814.20Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipASNDAscendis Pharma A/SN/ABMRNBioMarin Pharmaceutical98.71%Insider OwnershipCompanyInsider OwnershipASNDAscendis Pharma A/S40.00%BMRNBioMarin Pharmaceutical0.85%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableASNDAscendis Pharma A/S1,18962.38 million37.43 millionOptionableBMRNBioMarin Pharmaceutical3,221193.28 million191.64 millionOptionableASND and BMRN HeadlinesRecent News About These Companies5 Stocks That Could 10X by 2030May 29 at 7:51 PM | insidermonkey.comBioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Receives Consensus Rating of "Moderate Buy" from BrokeragesMay 29 at 2:53 AM | americanbankingnews.comBioMarin Pharmaceutical (BMRN) Receives a Hold from Stifel NicolausMay 25, 2026 | theglobeandmail.comBioMarin Pharmaceutical Inc. $BMRN Shares Bought by Systematic Financial Management LPMay 25, 2026 | marketbeat.comSwedbank AB Has $47.35 Million Stock Holdings in BioMarin Pharmaceutical Inc. $BMRNMay 25, 2026 | marketbeat.comLSV Asset Management Has $52.43 Million Position in BioMarin Pharmaceutical Inc. $BMRNMay 25, 2026 | marketbeat.comResona Asset Management Co. Ltd. Has $1.23 Million Position in BioMarin Pharmaceutical Inc. $BMRNMay 24, 2026 | marketbeat.comFideuram Intesa Sanpaolo Private Banking S.P.A. Invests $1.90 Million in BioMarin Pharmaceutical Inc. $BMRNMay 24, 2026 | marketbeat.comCatalyst Funds Management Pty Ltd Invests $1.24 Million in BioMarin Pharmaceutical Inc. $BMRNMay 24, 2026 | marketbeat.comBioMarin Pharmaceutical (NASDAQ:BMRN) Price Target Lowered to $111.00 at Canaccord Genuity GroupMay 23, 2026 | americanbankingnews.comBioMarin Pharmaceutical (NASDAQ:BMRN) Rating Increased to Buy at Wall Street ZenMay 23, 2026 | marketbeat.comAnalysts Offer Insights on Healthcare Companies: Vaxcyte (PCVX) and BioMarin Pharmaceutical (BMRN)May 22, 2026 | theglobeandmail.comAnalysts Offer Insights on Healthcare Companies: Summit Therapeutics (SMMT), BioMarin Pharmaceutical (BMRN) and Thermo Fisher (TMO)May 22, 2026 | theglobeandmail.comBioMarin Pharmaceutical (BMRN) Gets a Hold from Stifel NicolausMay 22, 2026 | theglobeandmail.com31,991 Shares in BioMarin Pharmaceutical Inc. $BMRN Purchased by Fideuram Intesa Sanpaolo Private Banking S.P.A.May 22, 2026 | marketbeat.comAnalysts Are Bullish on Top Healthcare Stocks: Relay Therapeutics (RLAY), BioMarin Pharmaceutical (BMRN)May 21, 2026 | theglobeandmail.comBioMarin's Voxzogo Meets Goal in Late-Stage Study for HypochondroplasiaMay 21, 2026 | zacks.comAnalysts Offer Insights on Healthcare Companies: InfuSystem Holdings (INFU) and BioMarin Pharmaceutical (BMRN)May 21, 2026 | theglobeandmail.comBioMarin stock surges on positive hypochondroplasia trial dataMay 21, 2026 | ca.investing.comBioMarin’s (BMRN) Phase 3 Trial of BMN 401 for ENPP1 Deficiency Meets One Co-Primary EndpointMay 21, 2026 | insidermonkey.comBioMarin (BMRN) Is Down 6.3% After Mixed Phase 3 BMN 401 Results in ENPP1 DeficiencyMay 21, 2026 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeASND and BMRN Company DescriptionsAscendis Pharma A/S NASDAQ:ASND$224.11 -13.36 (-5.63%) Closing price 05/29/2026 04:00 PM EasternExtended Trading$224.17 +0.06 (+0.03%) As of 05/29/2026 07:37 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.BioMarin Pharmaceutical NASDAQ:BMRN$57.29 +4.55 (+8.63%) Closing price 05/29/2026 04:00 PM EasternExtended Trading$57.16 -0.13 (-0.22%) As of 05/29/2026 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company's commercial products also comprise Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme, which is delivered through subcutaneous injection to reduce blood Phe concentrations; Brineura, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; Voxzogo, a once daily injection analog of c-type natriuretic peptide for the treatment of achondroplasia; and Aldurazyme, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase. In addition, it develops Roctavian, an adeno associated virus vector, for the treatment of patients with severe hemophilia A. The company serves specialty pharmacies, hospitals, and non-U.S. government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally. BioMarin Pharmaceutical Inc. has license and collaboration agreements with Sarepta Therapeutics, Ares Trading S.A., Catalyst Pharmaceutical Partners, Inc. The company was incorporated in 1996 and is headquartered in San Rafael, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 05/25 - 05/29 Gap Inc. Cuts Sales Outlook After Q1 Miss, Shares Drop 17% Costco’s Strong Quarter Still Leaves Investors With a Valuation Problem MongoDB's AI Advantage Is Starting to Show Up in Results Shares Fall, Targets Rise—Markets and Analysts Diverge on Synopsys Dollar Tree Keeps Winning After Family Dollar Divorce Salesforce Stock Finds Support as AI Momentum Builds These 3 Software Stocks Are Buying Back Shares Hand Over Fist Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
